Hexyrab-L Capsule SR is a sustained-release formulation combining Levosulpiride 75 mg and Rabeprazole 20 mg, designed for the management of gastrointestinal disorders characterized by dyspepsia, gastroesophageal reflux disease (GERD), and functional dysmotility. Levosulpiride, a selective dopamine D2 receptor antagonist, exerts prokinetic effects by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as bloating, nausea, and epigastric discomfort. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, promoting mucosal healing and reducing acid-related irritation. The combination therapy targets both motility dysfunction and acid hypersecretion, providing comprehensive symptom relief and improved patient outcomes. Hexyrab-L Capsule SR is indicated for patients with erosive esophagitis, non-ulcer dyspepsia, and other acid-peptic disorders where delayed gastric emptying and acid secretion coexist. The sustained-release formulation ensures prolonged therapeutic plasma levels, enhancing efficacy and patient compliance. Hexyrab-L should be administered as prescribed, with caution advised in patients with hypersensitivity to sulpiride or rabeprazole, severe renal or hepatic impairment, and those on concomitant medications that may interact adversely. Regular monitoring is recommended to assess therapeutic response and detect potential adverse effects.